Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL Brand of Combination Parasiticides for Companion Animals
Complements Merck Animal Health’s Broad Portfolio of Vaccines and Pharmaceuticals
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category from Virbac (NYSE Euronext:VIRP).
Comprehensive parasite protection is an essential part of canine overall health and well-being. “Our veterinary medicines, including parasiticides, and vaccines continue to transform the animal health industry and further solidify our position in the U.S. Companion Animal category,” said Rick DeLuca, president, Merck Animal Health. “The extensive breadth and depth of our product portfolio enhances our offerings of comprehensive pet care solutions, which provide a full range of complementary solutions for our customers to improve the health and well-being of animals and the people who care for them.”
Short URL: https://caninechronicle.com/?p=186657
Comments are closed